ES2166779T3 - Complejos inmunogenicos del hiv. - Google Patents
Complejos inmunogenicos del hiv.Info
- Publication number
- ES2166779T3 ES2166779T3 ES94917313T ES94917313T ES2166779T3 ES 2166779 T3 ES2166779 T3 ES 2166779T3 ES 94917313 T ES94917313 T ES 94917313T ES 94917313 T ES94917313 T ES 94917313T ES 2166779 T3 ES2166779 T3 ES 2166779T3
- Authority
- ES
- Spain
- Prior art keywords
- hiv
- immunogenic complexes
- complex
- vaccine
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002163 immunogen Effects 0.000 title 1
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- IAHFWCOBPZCAEA-UHFFFAOYSA-N succinonitrile Chemical compound N#CCCC#N IAHFWCOBPZCAEA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE PRESENTA UNA VACUNA Y UN METODO PARA ELEVAR LA NEUTRALIZACION DE ANTICUERPOS CONTRA LA INFECCION POR HIV. LA VACUNA COMPRENDE UN COMPLEJO DE GP120 COVALENTEMENTE UNIDO CON CD4 O A CONCANAVALINA DE SUCCINIL A. TAMBIEN SE HAN DESCUBIERTO PRUEBAS INMUNOLOGICAS QUE UTILIZAN EL COMPLEJO O LOS ANTICUERPOS PARA EL MISMO PARA LA DETECCION DE INFECCIONES POR HIV.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6092693A | 1993-05-07 | 1993-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2166779T3 true ES2166779T3 (es) | 2002-05-01 |
Family
ID=22032603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94917313T Expired - Lifetime ES2166779T3 (es) | 1993-05-07 | 1994-05-06 | Complejos inmunogenicos del hiv. |
Country Status (10)
Country | Link |
---|---|
US (6) | US5843454A (es) |
EP (1) | EP0699077B1 (es) |
JP (1) | JPH08510246A (es) |
AT (1) | ATE207760T1 (es) |
AU (1) | AU680916B2 (es) |
DE (1) | DE69428896T2 (es) |
DK (1) | DK0699077T3 (es) |
ES (1) | ES2166779T3 (es) |
PT (1) | PT699077E (es) |
WO (1) | WO1994026305A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165710A (en) * | 1989-10-23 | 2000-12-26 | Robinson; James E. | Method for immobilizing viral glycoproteins for use in solid-phase immunoassays |
US20040076636A1 (en) * | 1993-05-07 | 2004-04-22 | Ranajit Pal | HIV immunogenic complexes |
US20060159688A1 (en) * | 1996-05-15 | 2006-07-20 | Ragupathy Madiyalakan | Method for diagnosing efficacy of xenotypic antibody therapy |
US8038994B2 (en) * | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
EP1297846A1 (en) * | 1996-05-15 | 2003-04-02 | Altarex Corporation | Method and composition for reconforming multi-epitopic antigens to initiate an immune response |
AU3960797A (en) * | 1996-06-28 | 1998-01-21 | Dana-Farber Cancer Institute | Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection |
US7063850B1 (en) * | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
FR2789590B1 (fr) * | 1999-02-15 | 2003-01-17 | Inst Rech Developpement Ird | Compositions immunogenes utilisables comme vaccins |
US7115262B1 (en) | 1999-03-16 | 2006-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein for prevention and treatment of HIV infection |
US6908612B2 (en) | 1999-10-08 | 2005-06-21 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
US7311920B1 (en) | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
DK1137786T3 (da) * | 1999-10-08 | 2007-08-06 | Univ Maryland Biotech Inst | Viruscoatprotein/receptorkimærer og fremgangsmåder til brug heraf |
FR2799974B1 (fr) * | 1999-10-25 | 2001-11-30 | Aventis Pasteur | Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih |
US6503736B1 (en) * | 1999-11-12 | 2003-01-07 | BIOMéRIEUX, INC. | Antibodies to crosslinkers and methods for using the same |
JP2004511444A (ja) | 2000-09-22 | 2004-04-15 | デューク・ユニバーシティー | 免疫原 |
US7033593B2 (en) * | 2000-09-22 | 2006-04-25 | Duke University | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide |
US7276579B2 (en) * | 2000-12-27 | 2007-10-02 | Dana-Farber Cancer Institute, Inc. | Immunogenic proteoliposomes, and uses thereof |
AU2002335932B2 (en) * | 2001-03-21 | 2007-11-01 | Altarex Medical Corp. | Therapeutic compositions that alter the immune response |
EP1450857B1 (en) * | 2001-10-16 | 2010-09-15 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
WO2003086041A2 (en) * | 2002-04-11 | 2003-10-23 | Altarex Medical Corporation | Binding agents and their use in targeting tumor cells |
WO2003095492A1 (en) * | 2002-05-06 | 2003-11-20 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
WO2003092630A2 (en) * | 2002-05-06 | 2003-11-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries |
CA2482744C (en) * | 2002-05-07 | 2013-11-26 | Chiron Corporation | Hiv envelope-cd4 complexes and hybrids |
WO2004002500A1 (en) | 2002-06-28 | 2004-01-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
EP1518557A4 (en) * | 2002-06-28 | 2008-12-03 | Fuso Pharmaceutical Ind | ANTI-HIV AGENTS |
EP2374811A1 (en) * | 2002-07-23 | 2011-10-12 | Duke University | IgG Fc/HIV-gp120/c3d fusion protein |
JP4038679B2 (ja) * | 2003-05-13 | 2008-01-30 | 住友電気工業株式会社 | 半導体レーザーバーの固定用治具 |
US8637234B2 (en) * | 2004-04-16 | 2014-01-28 | Uab Research Foundation | Molecular scaffolds for HIV-1 epitopes |
CA2569562C (en) * | 2004-06-08 | 2013-12-03 | Vega Masignani | Fusion proteins comprising cd4 minimal modules and methods of use thereof |
WO2006026097A2 (en) * | 2004-08-25 | 2006-03-09 | Vijay Ramakrishnan | Pegylation of antibodies against hiv |
WO2006044410A2 (en) * | 2004-10-14 | 2006-04-27 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines |
AU2005302416A1 (en) * | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies |
ATE471947T1 (de) | 2005-02-03 | 2010-07-15 | Novartis Vaccines & Diagnostic | Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür |
WO2006091455A2 (en) * | 2005-02-18 | 2006-08-31 | Uab Research Foundation | Molecular scaffolds for hiv-1 immunogens |
CA2623197A1 (en) * | 2005-09-22 | 2007-03-29 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
US20100104580A1 (en) * | 2008-09-03 | 2010-04-29 | Philadelphia Health & Education Corporation D/B/A | Altered Immunogenic Landscape in HIV-1 Envelope Proteins |
US20110212119A1 (en) * | 2008-10-31 | 2011-09-01 | Proteonova, Inc. | Methods for making hiv vaccines and related compositions |
US8340810B2 (en) * | 2008-10-31 | 2012-12-25 | Spectra Logic Corp. | Robotic storage library with queued move instructions and method of queuing such instructions |
US9228171B2 (en) | 2010-02-05 | 2016-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulatory B cells (tBREGS) and their use |
ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
US9783594B2 (en) | 2011-05-17 | 2017-10-10 | The Rockefeller University | Human immunodeficiency virus neutralizing antibodies and methods of use thereof |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
US20150175678A1 (en) * | 2012-06-15 | 2015-06-25 | Beth Israel Deaconess Medical Center, Inc. | IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3074419B1 (en) | 2013-11-25 | 2018-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
US20160362478A1 (en) * | 2014-02-10 | 2016-12-15 | Navid Madani | Cd4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies |
US9975848B2 (en) | 2014-08-13 | 2018-05-22 | The Trustees Of The University Of Pennsylvania | Inhibitors of HIV-1 entry and methods of use thereof |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2011299A1 (en) * | 1989-03-03 | 1990-09-03 | Franklin Volvovitz | Aids therapy |
EP0550516A1 (en) * | 1990-09-28 | 1993-07-14 | Hospital For Joint Diseases | Method for inhibiting the infectivity of human immunodeficiency virus |
-
1994
- 1994-05-06 AU AU69073/94A patent/AU680916B2/en not_active Ceased
- 1994-05-06 ES ES94917313T patent/ES2166779T3/es not_active Expired - Lifetime
- 1994-05-06 WO PCT/US1994/005020 patent/WO1994026305A1/en active IP Right Grant
- 1994-05-06 US US08/464,680 patent/US5843454A/en not_active Expired - Lifetime
- 1994-05-06 JP JP6525565A patent/JPH08510246A/ja active Pending
- 1994-05-06 DE DE69428896T patent/DE69428896T2/de not_active Expired - Lifetime
- 1994-05-06 EP EP94917313A patent/EP0699077B1/en not_active Expired - Lifetime
- 1994-05-06 AT AT94917313T patent/ATE207760T1/de active
- 1994-05-06 PT PT94917313T patent/PT699077E/pt unknown
- 1994-05-06 DK DK94917313T patent/DK0699077T3/da active
-
1995
- 1995-05-08 US US08/437,250 patent/US5518723A/en not_active Expired - Lifetime
-
1998
- 1998-05-11 US US09/075,544 patent/US6030772A/en not_active Expired - Lifetime
-
2000
- 2000-01-07 US US09/479,675 patent/US6328973B1/en not_active Expired - Fee Related
-
2001
- 2001-07-17 US US09/905,963 patent/US6465172B1/en not_active Expired - Fee Related
- 2001-07-17 US US09/905,962 patent/US20030039663A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE207760T1 (de) | 2001-11-15 |
US6465172B1 (en) | 2002-10-15 |
WO1994026305A1 (en) | 1994-11-24 |
AU680916B2 (en) | 1997-08-14 |
US5518723A (en) | 1996-05-21 |
DE69428896D1 (de) | 2001-12-06 |
US20030039663A1 (en) | 2003-02-27 |
EP0699077A1 (en) | 1996-03-06 |
EP0699077B1 (en) | 2001-10-31 |
US6030772A (en) | 2000-02-29 |
US5843454A (en) | 1998-12-01 |
PT699077E (pt) | 2002-04-29 |
DE69428896T2 (de) | 2002-06-20 |
JPH08510246A (ja) | 1996-10-29 |
US6328973B1 (en) | 2001-12-11 |
AU6907394A (en) | 1994-12-12 |
DK0699077T3 (da) | 2002-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2166779T3 (es) | Complejos inmunogenicos del hiv. | |
ES2098029T3 (es) | Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado. | |
ES2104556T3 (es) | Peptidos que tienen propiedades inmunologicas de hiv-2. | |
FI903292A0 (fi) | T-cellepitop som baerarmolekyler foer konjugerade vacciner. | |
BG95337A (bg) | Ваксиниране и методи срещу заболявания,резултат от патогенни отговори на т-клетъчно специфични популации | |
ES2152421T3 (es) | Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas. | |
ES2032802T3 (es) | Sucedaneo de la sangre, semisintetico, extrapuro. | |
ES2118109T3 (es) | Antigenos polisacaridos de streptococcus pneumoniae. | |
ATE306938T1 (de) | Verwendung von cpg als adjuvans für hivimpstoff | |
YU28392A (sh) | Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a | |
AP2002002592A0 (en) | Vaccine for the prophylactic or therapeutic immunization against HIV. | |
ES2174837T3 (es) | Conjugados de saponina-antigeno y su utilizacion. | |
CY1108299T1 (el) | Πεπτιδια του ιου ανθρωπινης ανοσοανεπαρκειας (hiv), αντιγονα και συνθεσεις εμβολιου | |
AR114627A1 (es) | Composición inmunogénica | |
ES2530769T3 (es) | Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno | |
EP2302059A8 (en) | Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization | |
ES2074062T3 (es) | Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda. | |
BR9610679A (pt) | Antígenos de leishmania para uso na terapia e disgnose da leishmaniose | |
ES2194836T3 (es) | Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana. | |
DE69029937D1 (de) | FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER | |
ATE182271T1 (de) | Arzneimittel zur behandlung von krebs, aids und viruserkrankungen | |
ES2059305T3 (es) | Proteina del virus de la seudorrabia. | |
IL86675A (en) | Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same | |
EP0385909A3 (en) | A kit or composition for the prevention or treatment of HIV-1 infections | |
HK1035141A1 (en) | Methods and compositions for detection and diagnosis of infectious diseases. |